Pharma Focus Asia

U.S. Government and Novavax Extend Partnership

Monday, February 13, 2023

Novavax announced a modification to its existing agreement with the U.S. Department of Health and Human Services (HHS), in collaboration with the Department of Defence, to deliver up to 1.5 million doses of the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373).

This agreement will maintain the U.S. public's access to Novavax' vaccine and support the development of smaller dose vials, strain selection in line with U.S. Food and Drug Administration (FDA) recommendations, and a smooth transition to the commercial market.

This contract will support the U.S. government's continued efforts to make Novavax' protein-based vaccine available for free to states, jurisdictions, federal pharmacy partners and federally qualified health centres.

This agreement offers the American people a diverse COVID-19 vaccine portfolio and underscores the importance of Novavax' partnership with the U.S. government to ensure continuous access to a protein-based option as part of public health measures. This collaboration with the U.S. government on the development of COVID-19 vaccine will meet the requirements of the FDA and the commercial customers for the upcoming 2023/2024 vaccination campaign.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024